secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2026-07-01T21:00:22+00:00
Accession:  0001171843-26-004428
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics reports tovecimig Phase 2/3 COMPANION-002 met primary endpoint; BLA filing planned
--------------------------------------------------------------------------------

- Tovecimig + paclitaxel achieved ORR 18.0% vs 5.3% paclitaxel alone (p=0.0228); median PFS 4.7 vs 2.6 months (HR=0.44, p<0.0001).
- OS analysis confounded by 54% crossover; post-hoc subset shows median OS 12.8 mo for crossover patients vs 6.1 mo for no-crossover (HR=0.54, p=0.04).
- Cash and marketable securities $195M as of Q1 2026; runway into 2028. FDA meeting expected Q3 2026, BLA filing late 2026, potential approval 2H 2027.
- Pipeline includes CTX-8371 (PD-1xPD-L1) with deep responses in TNBC, HL, NSCLC; CTX-471 (CD137) Phase 2 in NCAM+ tumors mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/0001171843-26-004428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184326004428/f8k_070126.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-004428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer